Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

Glioblastoma (GBM) is highly aggressive and has a poor prognosis. Belinostat is a histone deacetylase inhibitor with blood–brain barrier permeability, anti-GBM activity, and the potential to enhance chemoradiation. The purpose of this clinical trial was to assess the efficacy of combining belinostat...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Karen Xu, Karthik Ramesh, Vicki Huang, Saumya S. Gurbani, James Scott Cordova, Eduard Schreibmann, Brent D. Weinberg, Soma Sengupta, Alfredo D. Voloschin, Matthias Holdhoff, Peter B. Barker, Lawrence R. Kleinberg, Jeffrey J. Olson, Hui-Kuo G. Shu, Hyunsuk Shim
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI AG 2022-03-01
Edice:Tomography
Témata:
glioblastoma
histone deacetylase
epigenetic drug
radiation sensitizer
magnetic resonance spectroscopy
On-line přístup:https://www.mdpi.com/2379-139X/8/2/57
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky